SwitzerlandSwitzerland

Half of European men are related to King Tut

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and half of all Western European men are related to King Tut. Using material made by a film team of the Discovery Channel, the scientists at iGENEA apparently reconstructed the Y-DNA profile of the boy Pharaoh, who ascended the throne at the age of nine, his father Akhenaten and grandfather Amenhotep III.
The result of the DNA-tests show that King Tut belonged to haplogroup R1b1a2, which more than 50 percent of all men in Western Europe belong to, iGENEA said in a statement. In Egypt, the haplogroup R1b1a2 is estimated to be less than one percent, which researchers believe was partly caused by European immigration during the last 2,000 years. “Since paternal ancestry of King Tut is unknown, therefore it is not clear at this point of time, how this lineage came from its region of origin to Egypt,” the IGENEA-scientists said. The R1b1a2-lineage is believed to have originated about 9,500 years ago in the Black Sea region, adding that the haplogroup began to migrate to Europe with the spread of agriculture since 7,000 BC.
Along with the discovery, iGENEA made another announcement this week: it is now selling a DNA testing service for those who would like to know if they are related to King Tut. For between 139 and 399 euros.

SwitzerlandSwitzerland

30.03.2012

Basel/Hinxton (UK) – Two European teams have created huge repositories of cancer genomics data that help predict drug response. Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale...

SwitzerlandSwitzerland

27.03.2012

London/Lausanne – The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which...

SwitzerlandSwitzerland

26.03.2012

Basel/Vienna - Following promising results from a Phase III study, Roche has submitted a regulatory application to EMA for subcutaneous Herceptin (trastuzumab) to treat HER2-positive breast cancer. Roche said subcutaneous...

SwitzerlandSwitzerland

09.03.2012

After the US Food & Drug Administration forced Swiss generics giant Sandoz AG to update its production facilities in Quebec, there are now fears that supplies of some medicines could grow tight in Canada. The regulatory authority...

SwitzerlandSwitzerland

08.03.2012

The hepatitis C space has seen a string of large deals in the last weeks that include a US$11bn buyout of Pharmasset by Gilead. Now Novartis is also trying to get in the game with the purchase of a global exclusive licence from...

SwitzerlandSwitzerland

06.03.2012

Allschwil – Swiss Actelion Ltd. has strengthened its commercial offerings by securing rights in certain countries to Auxilium’s biotech drug Xiaflex for treating tissue buildup under the skin. The US pharma is to receive US$10m...

SwitzerlandSwitzerland

06.03.2012

Zug – Life Sciences specialist HBM partners has raised €90m in the first close of its HBM BioCapital II fund, which will invest in revenue-generating companies in the pharmaceuticals, medical device and diagnostics sectors....

SwitzerlandSwitzerland

05.03.2012

Stans – Mondobiotech, a drug discovery company in troubled waters, could soon be under Italian ownership: The Swiss biotech announced it has entered into exclusive negotiations with Milan-based provider of pharmaceutical and...

Displaying results 1 to 10 out of 276

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-switzerland/article/half-of-european-men-are-related-to-king-tut.html

Product of the week

Products

Events

All Events

Current issue

All issues